On this week's episode of the Business of Biotech we're speaking with Alan Bash, President, Carvykti, at Legend Biotech, about how Carvykti became a blockbuster, category-leading CAR T therapy for multiple myeloma.
This deep dive into a successful rescue mission of a Type 1 Diabetes clinical trial reveals how shifting to a direct-to-patient digital strategy can turn a failing timeline into a success story.
Discover how structured design-of-experiment approaches can optimize charge variants and glycosylation to enhance biologics quality and therapeutic performance.
To strengthen cross-functional performance, teams should commit to building shared understanding, improving communication, and continuously refining their approach.
Let’s talk about some tangible building blocks necessary to achieve the next evolution of patient support and explore the effects of strategic payment, budgeting, and logistics solutions.
Find out what 19 US payer organizations revealed about CGT coverage decisions, pre-approval engagement timelines, and the clinical evidence they need most to approve high-cost therapies.
Automated data flows and human‑guided AI enable faster, more reliable oversight into clinical trials. Learn how real‑time insights and unified monitoring support quality, efficiency, and readiness.
